“LORLATINIB IN CRISOTINIB-RESISTANT ALK+ NSCLC PATIENTS. OUR RESULT”, Вопр. онкол., vol. 65, no. 3, pp. 386–392, Mar. 2019, doi: 10.37469/0507-3758-2019-65-3-386-392.